IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

666.44 4.27 −0.64%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. (IDXX) Operating cash flow

Alert me on Operating cash flow

IDEXX Laboratories, Inc.'s operating cash flow for fiscal 2025 was $1.2B, up 27.2% from $929.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from $221.8M (fiscal 2015) to $1.2B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 7th of 49 Diagnostics & Research companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $1.2B 27.21%
FY2024 $929.0M 2.48%
FY2023 $906.5M 66.95%
FY2022 $543.0M (28.13%)
FY2021 $755.5M 16.59%
FY2020 $648.1M 41.14%
FY2019 $459.2M 14.77%
FY2018 $400.1M 7.18%
FY2017 $373.3M 10.13%
FY2016 $338.9M 52.81%

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $449.7M 29.54%
Jun 2026 $347.2M 30.39%
Mar 2026 $266.2M (25.16%)
Dec 2025 $355.8M (11.58%)
43 more quarters

Against its own ten years

Low $221.8M High $1.2B
Ten-year median $543.0M
Current reading's percentile 100

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on IDXX